-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $250 at RBC Capital
-
-
-
-
-
-
-
Ascendis Pharma's (ASND) PDUFA Disclosure Removes Near-Term Stock Upside - Stifel
-
-
-
-
-
-
-
Ascendis submits European approval application for achondroplasia drug
-
-
-
-
-
-
-
Ascendis Pharma (ASND) PT Raised to $201 at BofA Securities
-
-
-
-
-
-
-
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
-
-
-
-
-
-
-
Ascendis Pharma (ASND) to Present Latest Clinical and Quality-of-Life Data for TransCon PTH-Treated Adults with Chronic Hypoparathyroidism
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

